This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Estimated benefits used in the economic analysis
The expected QALYs were 25.11120 with no prophylaxis and 25.11383 with prophylaxis (difference 0.00263).
Cost results
The expected costs were $22.60 with no prophylaxis and $126.60 with prophylaxis (difference $104).
Synthesis of costs and benefits
An incremental cost-utility ratio was calculated to combine the costs and QALYs of the two strategies.
The incremental cost per QALY gained with prophylaxis over no prophylaxis was $39,545, which is below the commonly cited threshold of $50,000 per QALY.
The results of the sensitivity analysis showed that the most influential parameters were the cost of intermittent pneumatic compression, the effectiveness of intermittent pneumatic compression, and the probability of having a DVT after Caesarean. Specifically, the incremental cost per QALY gained with prophylaxis remained below $50,000 as long as the incidence of post-Caesarean DVT (both symptomatic and asymptomatic) was at least 0.68%, intermittent pneumatic compression reduced the change of DVT by at least 50%, or the cost of intermittent pneumatic compression was less than $180.
Authors' conclusions
Thromboprophylaxis using intermittent pneumatic compression represents a cost-effective strategy in women undergoing Caesarean, although the results are highly dependent on variables such as the effectiveness of prophylaxis and the cost of compression boots.
CRD COMMENTARY -Selection of comparators
The choice of the comparators appears to have been appropriate in that both strategies (prophylaxis and no prophylaxis) are recommended in different settings and for women at different risk for DVT. For example, the authors stated that routine thromboprophylaxis is not standard practice in the USA. You should decide whether they are valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The clinical data were derived from published studies. However, no systematic search for data was performed. In effect, it appears that the primary studies have been identified selectively rather than through a systematic review of the literature. No information on the primary studies was given, which means that it is not possible to make an objective assessment of the validity of the clinical estimates used in the model.
Validity of estimate of measure of benefit
The benefits (QALYs) were modelled using the Markov model. The sources of utility weights used to calculate the QALYs were not described, thus the approach used to derive quality of life was not clear.
Validity of estimate of costs
The categories of costs included in the analysis were consistent with the authors' stated perspective. As for the other methodological aspects of the analysis, little information was provided on the cost analysis. The costs were presented as macro-categories and a breakdown of items was provided only for the treatment of an episode of DVT. Details on the unit costs and quantities of resources used were not reported, which limits the possibility of replicating the analysis in other settings. Statistical analyses were not performed, but the impact of variations in cost estimates was investigated in the sensitivity analysis. The price year was reported, which enhances the generalisability of the study results to other time periods.
